MT-2 10mg Peptide: Research Overview & Protocol Guide

In cellular signaling and physiological research, synthetic melanocortin receptor agonists represent a major focus of scientific study. The MT-2 10mg peptide (Melanotan II) is a cyclic heptapeptide analog of the naturally occurring \alpha-melanocyte-stimulating hormone (\alpha-MSH), engineered for high receptor affinity and extended biological stability.

By interacting non-selectively across multiple melanocortin receptors (primarily MC1R, MC3R, MC4R, and MC5R), MT-2 peptides provide researchers with a versatile laboratory tool to evaluate melanogenesis, central appetite modulation, sexual function, and systemic neuroinflammatory signaling.

Technical Specifications & Product Details

Attribute	Specification Details
Form	Lyophilized (freeze-dried) powder
Vial Capacity	10mg total mass
Sequence Class	Cyclic melanocortin receptor agonist
Purity Standard	\ge 98\% purity benchmark
Physical Appearance	Solid, uniform white cake

Research Context & Scientific Applications

Reference Literature Focus

In scientific literature, research involving MT-2 centers on its potent binding affinity across central and peripheral melanocortin receptors:

• MC1R Signaling (Melanogenesis): Activation of MC1R in epidermal melanocytes stimulates eumelanin synthesis, promoting skin pigmentation independently of ultraviolet (UV) radiation.
• MC4R Signaling (Metabolic & Sexual Pathways): Central MC4R agonism in the hypothalamus influences energy balance, suppresses food intake, and regulates sexual arousal mechanisms in both male and female animal models.
• Neuroprotective Effects: Emerging literature explores melanocortin receptor activation in neuroinflammatory models to observe its capacity to attenuate pro-inflammatory cytokine expression.

Study Design Notes

The 10mg vial capacity provides a standard, reliable mass for establishing dilution curves across multiple experimental groups. Utilizing uniform batch lots ensures consistent receptor activation profiles throughout longitudinal trials.

Compliance Notice: MT-2 is designated strictly for laboratory research, in vitro testing, and non-clinical scientific evaluation. It is not approved for human consumption, direct medical treatment, or clinical diagnostic use.

Dosing & Protocol Guidelines

Peptide Handling Reference

Melanocortin peptides contain cyclic structures held together by specific covalent bonds. While relatively stable compared to linear peptides, exposure to rapid temperature changes, violent shaking, or extreme pH shifts can cause peptide degradation. Always handle research vials with care.

Step-by-Step MT-2 10mg Reconstitution Protocol

To properly reconstitute a 10mg vial of MT-2 in a controlled laboratory setting, follow this standardized sequence:

1. Thermal Equalization
   Prerequisite
   Remove the lyophilized 10mg vial from cold storage. Allow the glass vial to rest at room temperature for 15 to 20 minutes prior to introducing solvent to prevent thermal shock.
2. Slow Solvent Introduction
   Dilution
   Sanitize the rubber stopper with an alcohol wipe. Using a sterile syringe, slowly introduce bacteriostatic water down the interior glass wall of the vial. Avoid directing the liquid stream straight onto the powder cake.
3. Gentle Rotation
   Dissolution
   Do not shake the vial. Gently roll the vial between your palms or swirl it smoothly in circles until the white cake dissolves completely into a clear liquid.

Storage Requirements

• Unreconstituted Powder: Store long-term in a laboratory freezer at -20^\circ\text{C}, protected from light exposure, to maintain stability for up to 24 months.
• Reconstituted Liquid Solution: Store in a specialized refrigeration unit continuously between 2^\circ\text{C} and 8^\circ\text{C}. Protect from direct light. For maximum experimental precision, utilize reconstituted solutions within 28 days of preparation.

Side Effects & Safety Observations

Safety Observations

Data drawn from preclinical literature demonstrate a characteristic set of physiological responses associated with central melanocortin receptor stimulation:

• Systemic Responses: Transient facial flushing, mild nausea, and suppressed appetite are frequently observed during early exposure phases in animal models.
• Dermal Alterations: Darkening of existing nevi (moles) and hyperpigmentation of cutaneous tissue following repeated administration.
• Spontaneous Erection Response: Central MC4R agonism frequently induces penile erections in male animal models.

Contraindications

Research protocols incorporating MT-2 should exclude experimental models displaying:

• Pre-existing dysplastic nevi, active melanoma, or high-risk skin cancer profiles.
• Uncontrolled cardiovascular disease or hypertension, as melanocortin agonism can induce minor, transient blood pressure increases.
• Pregnancy or lactation models due to an absence of comprehensive embryonic safety data.

Interaction Review

Co-administering MT-2 alongside other potent sympathomimetic agents or appetite suppressants requires careful baseline monitoring. Combining the compound with unmonitored central nervous system agents should be executed with proper controls to maintain clear trial baselines.

COA & Testing Integrity

Certificate of Analysis (COA)

To guarantee trial validity and batch consistency, every lot of MT-2 10mg must undergo analytical verification by an independent, third-party laboratory. A fully compliant COA verifies:

1. Mass Spectrometry (MS): Confirms the precise molecular weight and cyclic sequence identity of the MT-2 peptide chain.
2. High-Performance Liquid Chromatography (HPLC): Measures the absolute purity level of the batch, ensuring it meets or exceeds the required 98% purity standard without chemical synthesis contaminants.

Quality Inspection Checklist

Prior to introducing a new reconstituted batch into an active research sequence, verify the following parameters:

• The protective flip-off cap is fully intact and shows no signs of physical tampering.
• Independent MS and HPLC test reports directly correspond to the lot number printed on the vial label.
• The lyophilized powder forms a solid, uniform white cake free from moisture or discoloration.
• Post-reconstitution solution appears entirely clear, colorless, and free of suspended particulate matter.